THIS INITIATIVE HAS BEEN SUPPORTED BY HELSINN THROUGH AN UNRESTRICTED EDUCATIONAL GRANT TO
MAGDALEN MEDICAL PUBLISHING LTD
ASH 2018: A promising future for high-risk AML patients
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX gives an update on the exciting news in acute myeloid leukemia (AML) from ASH 2018. With the fast approval of novel agents such as FLT3, IDH and BCL-2 inhibitors, and the combination of these agents with high-dose chemotherapy and hypomethylating agents, this is an extremely promising time for high-risk AML patients
HDAC inhibitors for AML: a platform on which to build other compounds and combinations?
Prof. Garcia-Manero discusses how HDAC inhibitors fit within the AML treatment landscape, talking about the encouraging future of the phase III pracinostat trial for older patients with high-risk AML. This trial has the potential to open the door for multiple interesting combinations.
New horizons in high-risk AML
Leading AML experts discuss novel therapeutic approaches and clinical trial data for high-risk AML.
Featuring exclusive interviews with Dr. Garcia-Manero on the use of HDAC inhibitors in the treatment of AML and roundtable discussions on best practise approaches.
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates
The content of VJHemOnc is intended for healthcare professionals